The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Evaluation of the Abuse Liability of Modafinil and Other Drugs for Excessive Daytime Sleepiness Associated with Narcolepsy
Abstract
Psychostimulants have been used routinely for the treatment of the disabling daytime sleepiness associated with narcolepsy. However, the perceived and real potential for abuse of amphetamine and amphetaminelike stimulants prompted a search for new wake-promoting compounds with lower dependency and abuse liabilities. Modafinil is a novel wake-promoting agent with a mechanism of action that differs markedly from that of amphetamine and amphetamine-like stimulants. In controlled clinical trials, modafinil has been shown to be an effective and well-tolerated treatment for excessive daytime sleepiness (EDS) in patients with narcolepsy. With a benzhydrylsulfinylacetamide structure, modafinil has a low level of solubility in water (< 1 mg/mL) and is unstable at temperatures > or = 180 degrees C, physicochemical properties that reduce the potential for its abuse via intravenous injection and smoking, respectively. Available preclinical and clinical data on the abuse liability of modafinil suggest a much lower potential for abuse and dependency than amphetaminelike stimulants commonly used for treating EDS in patients with narcolepsy. Therefore, modafinil represents a valuable therapeutic option for the treatment of EDS associated with narcolepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80949-6 · Cited by 5,501
Narcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095 · cited 3×
“It has been speculated that modafinil by activating the hypocretin (orexin) system of the lateral hypothalamus, may orchestrate the activity of critically important areas of the CNS involved in control of arousal and sleep-wake cycle by stimulating arousal regions, primarily via its dense projections to the tubero-mam…”
BackgroundLin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong, P. J., Nishino, S., & Mignot, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81965-0 · Cited by 2,613
Hypocretin (orexin) deficiency in human narcolepsy
Nishino, S., Ripley, B., Overeem, S., Lammers, G. J., & Mignot, E. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05582-8 · Cited by 1,776 · cited 1×
“In addition, recently, hypocretin-1 (orexin A) deficiency was documented in the cerebrospinal fluid of seven of nine patients with classical narcolepsy (28).”
BackgroundMartin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943
Self-citationLin, J.-S., Hou, Y., & Jouvet, M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14128 · Cited by 300
Broughton, R. J., Fleming, J. A. E., George, C. F. P., Hill, J. D., Kryger, M. H., Moldofsky, H., Montplaisir, J. Y., Morehouse, R. L., Moscovitch, A., & Murphy, W. F. (1997) · Neurology · doi:10.1212/wnl.49.2.444 · Cited by 288
An evaluation of the abuse potential of modafinil using methylphenidate as a reference
Jasinski, D. R. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400107 · Cited by 238
Self-citationSiegel, J. M. (1999) · Cell · doi:10.1016/s0092-8674(00)81969-8 · Cited by 234
Duteil, J., Rambert, F. A., Pessonnier, J., Hermant, J.-F., Gombert, R., & Assous, E. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90591-s · Cited by 220
Cited by
Volkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G.-J., Jayne, M., Hooker, J. M., Wong, C., et al. (2009) · JAMA · doi:10.1001/jama.2009.351 · Cited by 529
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391
A Systematic Review of Modafinil: Potential Clinical Uses and Mechanisms of Action
Ballon, J. S., & Feifel, D. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0406 · Cited by 349
Modafinil as Adjunct Therapy for Daytime Sleepiness in Obstructive Sleep Apnea
PACK, A. I., BLACK, J. E., SCHWARTZ, J. R. L., & MATHESON, J. K. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2103032 · Cited by 324
What Keeps Us Awake: the Neuropharmacology of Stimulants and Wakefulness Promoting Medications
Boutrel, B., & Koob, G. F. (2004) · Sleep · doi:10.1093/sleep/27.6.1181 · Cited by 307
Metadata
- Authors
- Jasinski, D. R., & Kovačević-Ristanović, R.
- Venue
- Clinical Neuropharmacology
- Published
- 2000-05
- Volume
- 23
- Issue
- 3
- Pages
- 149-156
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2040480454
- Cited by
- 292
- References
- 35
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the Abuse Liability of Modafinil and Other Drugs for Excessive Daytime Sleepiness Associated with Narcolepsy. https://app.cochat.ai/papers/10.1097/00002826-200005000-00004
- The paper
- Jasinski, D. R., & Kovačević-Ristanović, R. (2000). Evaluation of the Abuse Liability of Modafinil and Other Drugs for Excessive Daytime Sleepiness Associated with Narcolepsy. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-200005000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.